Media & Investors
Transparency is important to us. Find important information about Kuros Biosciences here – from our corporate documents to our current share price.
30 Jan 2020
Kuros reports publication of MagnetOs preclinical data demonstrating superiority to market-leading synthetic bone grafts in spinal fusion
03 Dec 2019
Kuros announces final result of Capital Increase – total gross proceeds of CHF 12.5 million raised
Reports & corporate governance
Kuros Biosciences is fully committed to good corporate governance and adherence to high ethical standards. Our principles and rules on corporate governance and ethical conduct are articulated in the Articles of Association, the Internal Regulations, the charters of the committees of our board of directors, and our code of conduct.
Olav Zilian, MD, PhD, EMBA
Mirabaud Securities Ltd
David Sherman, Ph.D.(AC)
Please use the button below to view and download Analyst reports
|Mar 26, 2020||Kuros will publish its Annual Report for 2019|
|Apr 21, 2020||Kuros will hold its Annual Shareholders' Meeting|
|Aug 12, 2020||Kuros will publish its Half Year Report for H1 2020|